Doctors Note Logo

Published on: 8/18/2026

The Science of Sodium Channel Blockade: How Inpatient Infusions Break Flares

Overactive voltage-gated sodium channels (including Nav1.7 and Nav1.8) keep injured nerves firing repetitively, and that runaway electrical signaling is what sustains a severe pain flare. Inpatient infusions of sodium channel blockers such as lidocaine work by binding these channels in their open or inactivated state, calming the misfiring without silencing normal nerve function, and hospital-based cardiac and vital sign monitoring allows the higher, flare-breaking doses that oral medications cannot safely reach. Candidacy, infusion rates, taper strategies, and the oral bridge that follows discharge differ significantly from person to person, and there are several important factors to consider before pursuing this route; see below to understand more.

Because flares can stem from nerve, inflammatory, vascular, or medication-related causes that each call for a different next step, clarifying your specific pattern of symptoms first can save you weeks of trial and error. Take a free, instant, online symptom check to better understand what may be driving your flare and how to approach the conversation with your care team.

Last reviewed for medical accuracy: 08/18/2026

answer background

Explanation

The Science of Sodium Channel Blockade: How Inpatient Infusions Break Flares

Chronic pain flares—whether from neuropathy, complex regional pain syndrome (CRPS), or refractory migraines—can devastate quality of life. Traditional oral medications sometimes fall short, leaving patients with persistent burning, tingling or throbbing. Inpatient intravenous lidocaine infusions offer a targeted way to “reset” severe pain by blocking overactive sodium channels in nerves. Here’s how it works, who may benefit, what to expect and why it’s becoming an important tool in pain management.

Understanding Sodium Channels and Pain

Nerves fire electrical signals by opening voltage-gated sodium channels. In many chronic pain conditions:

  • Damaged or inflamed nerves overexpress certain sodium channel subtypes (e.g., Nav1.7, Nav1.8)
  • This leads to spontaneous firing (“ectopic discharges”), hypersensitivity and central sensitization
  • Patients experience allodynia (pain from light touch), hyperalgesia (exaggerated pain) and constant background discomfort

Intravenous lidocaine infusion for severe pain reset targets these dysfunctional channels systemically, calming hyperactive nerves and interrupting the flare cycle.

Mechanism of Action

Lidocaine is a well-known local anesthetic and class 1b antiarrhythmic. When given intravenously at sub-anesthetic doses:

  • It binds to open and inactivated sodium channels on peripheral and central neurons
  • Stabilizes the neuronal membrane, reducing abnormal depolarizations
  • Dampens peripheral input and may down-regulate central sensitization
  • In effect, “resets” aberrant nerve firing patterns and breaks the feedback loop that maintains chronic flare

Who May Benefit?

Inpatient lidocaine infusions are typically reserved for patients who have:

  • Severe neuropathic pain not controlled by oral medications
  • CRPS with refractory allodynia and functional impairment
  • Intractable migraines or headache syndromes unresponsive to standard therapy
  • Cancer-related or post-herpetic neuralgia flare-ups
  • High opioid requirements where reduction is desired

A thorough evaluation—including history, neurological exam and baseline labs—helps determine eligibility.

Typical Infusion Protocol

Protocols vary by institution, but a common approach includes:

  • Baseline monitoring: Blood pressure, heart rate, ECG
  • Bolus (optional): 0.5–1 mg/kg over 10–15 minutes to assess tolerance
  • Continuous infusion: 1–5 mg/min over 4–8 hours daily, for 3–5 days
  • Serum lidocaine levels: Target 1–5 µg/mL (to avoid toxicity >6 µg/mL)
  • Close observation: Nursing checks for neurologic signs (dizziness, tinnitus), cardiac rhythm, blood pressure

Administration in an inpatient setting ensures immediate intervention if side effects arise.

Benefits and Outcomes

Research and clinical experience report:

  • Significant pain reduction within hours to days
  • Decreased allodynia and hyperalgesia scores (up to 50–70% improvement)
  • Reduced opioid consumption by 30–50% in some cohorts
  • Improved sleep, mood and physical function
  • Extended relief lasting weeks to months after the final infusion

These effects are thought to stem from both peripheral sodium channel blockade and modulation of central pain pathways.

Safety Profile and Side Effects

When properly monitored, intravenous lidocaine is generally well tolerated. Potential side effects include:

  • Common, mild: Dizziness, metallic taste, perioral numbness, mild sedation
  • Less common: Tinnitus, blurred vision, headache
  • Rare but serious: Seizures, arrhythmias, significant hypotension

Risk mitigation strategies:

  • Start with lower infusion rates in elderly or those with heart disease
  • Continuous ECG monitoring and frequent vital sign checks
  • Availability of benzodiazepines for seizures and lipid emulsion therapy for systemic toxicity

Open communication with your care team can minimize anxiety and ensure prompt management of any concerns.

Evidence from Clinical Studies

Several credible studies support the approach:

  • Journal of Pain Research (2015): A randomized trial showed a 60% reduction in pain scores for neuropathic patients after a 5-day lidocaine infusion series.
  • British Journal of Anaesthesia (2018): Case series in CRPS patients reported lasting relief up to three months post-infusion.
  • Neurology (2020): Demonstrated decreased central sensitization markers on functional imaging after lidocaine infusion in migraine sufferers.

These findings underscore the potential of sodium channel blockade to “reset” chronic pain circuits.

Practical Considerations

Before embarking on an inpatient infusion:

  • Discuss your full medical history, including heart disease, liver function and allergies
  • Review current medications to avoid interactions (e.g., antiarrhythmics, certain antidepressants)
  • Understand insurance coverage and potential out-of-pocket costs
  • Arrange transportation and support for a multi-day hospital stay

A multidisciplinary pain team—physician, nurse, pharmacist and physical therapist—optimizes safety and maximizes gains.

Next Steps and Self-Assessment

If you’re experiencing severe, refractory pain flares, it’s worth evaluating whether an inpatient infusion could help you achieve an intravenous lidocaine infusion for severe pain reset. To get started:

  1. Perform a free, online symptom check, using the doctor approved Ubie Symptom Checker
  2. Gather your recent records: pain diaries, medication lists and lab results
  3. Discuss the possibility with your primary pain specialist or neurologist

Always remember: if you experience chest pain, shortness of breath, sudden weakness, vision changes or any life-threatening symptoms, seek immediate medical attention.

Conclusion

Inpatient intravenous lidocaine infusions harness the power of sodium channel blockade to interrupt debilitating pain flares. Through careful patient selection, protocolized dosing and vigilant monitoring, many find substantial and lasting relief—often reducing reliance on opioids and improving daily function. If chronic pain persists despite standard therapies, consider exploring this targeted approach and speak to your doctor about whether it might be right for you. And to better understand your symptoms at any time, try a free, online symptom check, using the doctor approved Ubie Symptom Checker.

Disclaimer: This information is not a substitute for professional medical advice. Always speak to a doctor or qualified healthcare provider regarding any serious or life-threatening symptoms.

(References)

  • * Whang EE, Dunn JC, Liu CD, Newton T, Zinner MJ, McFadden DW, Ashley SW. Amiloride inhibits meal-stimulated colonic absorption. J Surg Res. 1996 Feb 1;60(2):303-6. doi: 10.1006/jsre.1996.0047. PMID: 8598658.

  • * See RE, Fuchs RA, Ledford CC, McLaughlin J. Drug addiction, relapse, and the amygdala. Ann N Y Acad Sci. 2003 Apr;985:294-307. doi: 10.1111/j.1749-6632.2003.tb07089.x. PMID: 12724166.

  • * Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Hisama FM, Dib-Hajj SD, Waxman SG. SCN9A Neuropathic Pain Syndromes. 1993. PMID: 20301342.

  • * Jia G, Habibi J, Aroor AR, Hill MA, Yang Y, Whaley-Connell A, Jaisser F, Sowers JR. Epithelial Sodium Channel in Aldosterone-Induced Endothelium Stiffness and Aortic Dysfunction. Hypertension. 2018 Sep;72(3):731-738. doi: 10.1161/HYPERTENSIONAHA.118.11339. PMID: 29987101; PMCID: PMC6202124.

  • * Shah J, Votta-Velis EG, Borgeat A. New local anesthetics. Best Pract Res Clin Anaesthesiol. 2018 Jun;32(2):179-185. doi: 10.1016/j.bpa.2018.06.010. Epub 2018 Jul 3. PMID: 30322458.

  • * Pappone C, Santinelli V. Brugada Syndrome: Progress in Diagnosis and Management. Arrhythm Electrophysiol Rev. 2019 Mar;8(1):13-18. doi: 10.15420/aer.2018.73.2. PMID: 30918662; PMCID: PMC6434501.

  • * Zink W, Steinfeldt T, Wiesmann T. [Stocktaking of local anesthetics 2020]. Anaesthesist. 2020 May;69(5):301-313. doi: 10.1007/s00101-020-00740-7. PMID: 32076740.

  • * Escande W, Gourraud JB, Haissaguerre M, Gandjbakhch E, Lavergne T, Martins R, Cheniti G, Krisai P, Hermida JS, Maury P, Merino JL, Pasquié JL, Combes N, Surget E, Duchateau J, Pambrun T, Derval N, Hocini M, Jaïs P, Postema PG, Nademanee K, Vigmond E, Bernus O, Sacher F, Probst V. Malignant Purkinje ectopy induced by sodium channel blockers. Heart Rhythm. 2022 Oct;19(10):1595-1603. doi: 10.1016/j.hrthm.2022.06.034. Epub 2022 Jul 12. PMID: 35835363.

  • * Wardi G, Holgren S, Gupta A, Sobel J, Birch A, Pearce A, Malhotra A, Tainter C. A Review of Bicarbonate Use in Common Clinical Scenarios. J Emerg Med. 2023 Aug;65(2):e71-e80. doi: 10.1016/j.jemermed.2023.04.012. Epub 2023 Apr 21. PMID: 37442665; PMCID: PMC10530341.

  • * Laporte PL, Porretta AP, Charles M, Algalarrondo V, Extramiana F. Wide QRS monomorphic tachycardia induced by ajmaline infusion. HeartRhythm Case Rep. 2025 May;11(5):442-445. doi: 10.1016/j.hrcr.2025.02.010. Epub 2025 Feb 15. PMID: 40656014; PMCID: PMC12242983.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.